Evidence map›Paper›PMID 35048324›Full record

ArticleMetabolic brain disease2022

Effect of curcumin nanoparticles on streptozotocin-induced male Wistar rat model of Alzheimer's disease.

Neveen A Noor, Eman N Hosny, Yasser A Khadrawy, Iman M Mourad, Amel I Othman, Heba S Aboul Ezz, Haitham S Mohammed

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. From Tradition to Translation: A Critical Appraisal ofInternational journal of molecular sciences · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Recent progress of nanomedicine in the treatment of Alzheimer's disease.Frontiers in cell and developmental biology · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Neveen A NoorZoology department, Faculty of Science, Cairo University, Giza, Egypt.
Eman N HosnyDepartment of Medical Physiology, Medical Division, National Research Center, El-Behouth St., Giza, Egypt.
Yasser A KhadrawyDepartment of Medical Physiology, Medical Division, National Research Center, El-Behouth St., Giza, Egypt. yaserask@yahoo.com.ORCID http://orcid.org/0000-0003-2562-535X
Iman M MouradZoology department, Faculty of Science, Cairo University, Giza, Egypt.
Amel I OthmanZoology department, Faculty of Science, Cairo University, Giza, Egypt.
Heba S Aboul EzzZoology department, Faculty of Science, Cairo University, Giza, Egypt.
Haitham S MohammedBiophysics Department, Faculty of Science, Cairo University, Giza, Egypt.
Cairo University · EGNational Water Research Center · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease that afflicts millions of people all over the world. Intracerebroventricular (ICV) injection of a sub-diabetogenic dose of streptozotocin (STZ) was established as an experimental animal model of AD. The present study was conducted to evaluate the efficacy of curcumin nanoparticles (CNs) against the behavioral, neurochemical and histopathological alterations induced by ICV-STZ. The animals were divided into: control animals, the animal model of AD that received a single bilateral ICV microinjection of STZ, and the animals protected by a daily oral administration of CNs for 6 days before the ICV-STZ injection. The animals of all groups were subjected to surgical operation on the 7th day of administration. Then the administration of distilled water or CNs was continued for 8 days. The ICV-STZ microinjection produced cognitive impairment as evident from the behavioral Morris water maze (MWM) test and induced oxidative stress in the cortex and hippocampus as indicated by the significant increases in lipid peroxidation and nitric oxide (NO) levels and the significant decrease in reduced glutathione (GSH) levels. It also produced a significant increase in acetylcholinesterase (AChE) and tumor necrosis-alpha (TNF-ɑ) and a significant decrease in Na+,K + -ATPase. In addition, a significant increase in amino acid neurotransmitters occurred in the hippocampus, whereas a significant decrease was obtained in the cortex of STZ-induced AD rats. CNs ameliorated the behavioral, immunohistochemical and most of the neurochemical alterations induced by STZ in the hippocampus and cortex. It may be concluded that CNs might be considered as a promising therapeutic agent for the treatment of AD.

Indexed as

Alzheimer DiseaseCurcuminNanoparticlesNeurodegenerative DiseasesAcetylcholinesteraseAnimalsDisease Models, AnimalHumansMaleMaze LearningOxidative StressRatsRats, WistarStreptozocinAcetylcholinesteraseCurcuminStreptozocinAmino acidsBrainCurcumin nanoparticlesImmunohistochemistryOxidative stressStreptozotocin

Identifiers

PMID35048324
OpenAlexW4206292509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.